Skip to main content
SpringerLink
Log in

Baricitinib-related AEs in patients with severe alopecia areata

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • King B, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology 188: 218-227, No. 2, 10 Feb 2023. Available from: URL: http://doi.org/10.1093/bjd/ljac059

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baricitinib-related AEs in patients with severe alopecia areata. Reactions Weekly 1945, 6 (2023). https://doi.org/10.1007/s40278-023-34087-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-34087-6

Search

Navigation